What is the present valuation and projected CAGR of the anti-neoplastic agents market?
The anti-neoplastic agents market size has grown strongly in recent years. It will grow from $130.01 billion in 2024 to $142.82 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing cancer incidence, growing demand for therapies, rising demand for minimally invasive cancer treatments, demand for affordable anti-neoplastic treatments.
The anti-neoplastic agents market size is expected to see strong growth in the next few years. It will grow to $202.12 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to patient education and awareness, government initiative, growing demand for personalized cancer treatment, growing focus on quality of life in cancer treatment. Major trends in the forecast period include advancements in oncology research, development of targeted therapies, biotechnology innovation, advancements in diagnostic tools.
Get Your Free Sample of The Global Anti-Neoplastic Agents Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12901&type=smp
What key drivers have fueled the anti-neoplastic agents market’s development over the years?
The increasing number of cancer cases is expected to propel the growth of the antineoplastic agent market going forward. Cancer is a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their normal boundaries and either spread to other organs or invade neighboring body parts. Antineoplastic agents play an essential role in cancer treatment by inhibiting cancer cell growth and division through various mechanisms, including DNA (Deoxyribonucleic acid) damage, cell cycle disruption and interference with crucial cellular pathways. For instance, in February 2024, according to the latest estimates of the global burden of cancer by the International Agency for Research on Cancer (IARC), a France-based international agency that promotes international collaboration in cancer research, the cancer burden is expected to grow to more than 35 million in 2050, a 77% increase over the estimated 20 million in 2022. Therefore, the increasing number of cancer cases is driving the growth of the antineoplastic agent market.
What is the segmentation for the anti-neoplastic agents market?
The anti-neoplastic agents market covered in this report is segmented –
1) By Type: Alkylating Agents, Antimetabolites, Hormones And Antagonists, Miscellaneous
2) By Disease Type: Gastrointestinal Cancer, Prostate Cancer, Lung Cancer, Breast Cancer, Other Disease Types
3) By End User: Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
Subsegments:
1) By Alkylating Agents: Nitrogen Mustards, Alkyl Sulfonates, Nitrosoureas, Triazines
2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues, Folate Antagonists
3) By Hormones and Antagonists: Estrogens and Antiestrogens, Androgens and Antiandrogens, Glucocorticoids
4) By Miscellaneous: Vinca Alkaloids, Taxanes, Antibiotic Antineoplastics, Targeted Therapy Agents
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/anti-neoplastic-agents-global-market-report
Who are the most influential companies in the anti-neoplastic agents market?
Major companies operating in the anti-neoplastic agents market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Fresenius SE & Co. KGaA, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Eisai Co. Ltd., Sun Pharmaceutical Industries Limited, Ipsen SA, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Intas Pharmaceuticals Limited, Hikma Pharmaceuticals PLC, Gland Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Jubilant Life Sciences Ltd., Lantheus Holdings Inc., Hutchison Medipharma Ltd., Natco Pharma Ltd., Accord Healthcare Limited, Qilu Pharmaceutical Co. Ltd.
What are the top industry trends projected to impact the anti-neoplastic agents market?
Major companies operating in the anti-neoplastic agent market are focused on developing clinical practices to sustain their position in the market. For instance, in March 2022, Novartis AG, a Switzerland-based pharmaceutical corporation, announced the Food and Drug Administration’s (FDA) approval of Pluvicto, a first targeted radioligand therapy for the treatment of progressive, PSMA (Prostate-specific membrane antigen) positive metastatic castration-resistant prostate cancer (mCRPC). It is recommended to provide 7.4 GBq (200 mCi) of Pluvicto intravenously every six weeks for a maximum of six doses or until disease progression or intolerable toxicity, whichever comes first. Based on PSMA expression in tumors, patients with previously treated mCRPC should be chosen for treatment with Pluvicto utilizing Locametz or another authorized PSMA-11 imaging agent.
What are the major regional insights for the anti-neoplastic agents market, and which region holds the top position?
North America was the largest region in the anti-neoplastic agents market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in anti-neoplastic agents market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Anti-Neoplastic Agents Market Report 2025 Offer?
The anti-neoplastic agents market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Anti-neoplastic agents refer to drugs that inhibit or destroy abnormal tissue growth, specifically targeting and combating cancerous cells in the body. They have a vital role in cancer treatment by disrupting the processes involved in tumor development and progression.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12901
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
